These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31101460)

  • 21. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
    Matsuoka T; Miwa Y; Tajika M; Sawada M; Fujimaki K; Soga T; Tomita H; Uemura S; Nishino I; Fukuda T; Sugie H; Kosuga M; Okuyama T; Umeda Y
    Mol Genet Metab Rep; 2016 Dec; 9():98-105. PubMed ID: 27896132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late form of Pompe disease with glycogen storage in peripheral nerves axons.
    Fidziańska A; Ługowska A; Tylki-Szymańska A
    J Neurol Sci; 2011 Feb; 301(1-2):59-62. PubMed ID: 21109266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
    Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
    Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Close monitoring of initial enzyme replacement therapy in a patient with childhood-onset Pompe disease.
    Ishigaki K; Murakami T; Nakanishi T; Oda E; Sato T; Osawa M
    Brain Dev; 2012 Feb; 34(2):98-102. PubMed ID: 21676566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-density areas on muscle CT in childhood-onset Pompe disease are caused by excess calcium accumulation.
    Ishigaki K; Mitsuhashi S; Kuwatsuru R; Murakami T; Shishikura K; Suzuki H; Hirayama Y; Nonaka I; Osawa M
    Acta Neuropathol; 2010 Oct; 120(4):537-43. PubMed ID: 20680637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights into therapeutic options for Pompe disease.
    Richard E; Douillard-Guilloux G; Caillaud C
    IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dilated Cerebral Arteriopathy in Classical Pompe Disease: A Novel Finding.
    Viamonte M; Tuna I; Rees J
    Pediatr Neurol; 2020 Jul; 108():117-120. PubMed ID: 32248988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
    Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
    J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy.
    McIntosh PT; Hobson-Webb LD; Kazi ZB; Prater SN; Banugaria SG; Austin S; Wang R; Enterline DS; Frush DP; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):85-91. PubMed ID: 29050825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
    Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.
    Gupta N; Kazi ZB; Nampoothiri S; Jagdeesh S; Kabra M; Puri RD; Muranjan M; Kalaivani M; Rehder C; Bali D; Verma IC; Kishnani PS
    J Pediatr; 2020 Jan; 216():44-50.e5. PubMed ID: 31606152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy.
    Avula S; Nguyen TM; Marble M; Lilje C
    Echocardiography; 2017 Apr; 34(4):621-624. PubMed ID: 28266734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left ventricular geometry, global function, and dyssynchrony in infants and children with pompe cardiomyopathy undergoing enzyme replacement therapy.
    Chen CA; Chien YH; Hwu WL; Lee NC; Wang JK; Chen LR; Lu CW; Lin MT; Chiu SN; Chiu HH; Wu MH
    J Card Fail; 2011 Nov; 17(11):930-6. PubMed ID: 22041330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perioperative management of children with glycogen storage disease type II-Pompe disease.
    Bosman L; Hoeks SE; González Candel A; van den Hout HJM; van der Ploeg AT; Staals LM
    Paediatr Anaesth; 2018 May; 28(5):428-435. PubMed ID: 29575534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Motor outcomes in patients with infantile and juvenile Pompe disease: Lessons from neurophysiological findings.
    Brassier A; Pichard S; Schiff M; Bouchereau J; Bérat CM; Caillaud C; Pion A; Khraiche D; Fauroux B; Oualha M; Barnerias C; Desguerre I; Hully M; Maquet M; Deladrière E; de Lonlay P; Gitiaux C
    Mol Genet Metab; 2023 Aug; 139(4):107650. PubMed ID: 37454519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.